SARS-CoV-2 continues to evolve under immunologic pressure. A synthesized version of pemivibart, an anti–SARS-CoV-2 monoclonal antibody with recent emergency-use authorization, showed mixed activity against emerging variants.
The New England Journal of Medicine: Search Results in Allergy/Immunology
